| Patient | Mahalia Jackson |
|---|---|
| Date of birth | 1911-10-26 |
| Identifiers | MRN HR-ML035-SYN-TD; SSN (made up) 000-35-4692 |
| Document date | 1964-08-24 |
| Author | Beatrice Fontenot, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Six-month review with the repeat FDG-PET. [S]
Ms. Jackson returns after about five and a half months of treatment. The repeat FDG-PET a week ago shows no remaining inflammation in the heart and much less in the lymph nodes, and the echocardiogram the same day shows an ejection fraction of 54 percent. She has taken prednisone 10 mg for three weeks and methotrexate 20 mg weekly. The laryngitis in June settled within ten days, and she has sung two concerts a week since late May without trouble. Her monthly methotrexate blood tests have been normal. The remote device checks show no ventricular tachycardia since March. She sleeps better on the lower dose and her appetite has settled. She would like to plan an autumn tour. She has had no thoughts of self-harm. [S]
| Element | Detail |
|---|---|
| FDG-PET and echocardiogram | No myocardial uptake; nodes smaller with low uptake; ejection fraction 54 percent from 47 |
| Treatment | Prednisone 10 mg; methotrexate 20 mg weekly |
| Device | No ventricular tachycardia since March; no shocks |
| Work | Two concerts a week since late May; autumn tour proposed |
| Laryngitis | Resolved within ten days |
| System | Result | Finding |
|---|---|---|
| Constitutional | Negative | Energy good; weight 93.0 kg; no fever |
| Respiratory | Negative | Breathless only on hills; no cough |
| Cardiovascular | Negative | No palpitations, shocks or fainting |
| Ears, nose, mouth, and throat | Negative | Voice back to normal; no mouth sores |
| Eyes | Negative | No redness or blurred vision |
| Psychiatric | Negative | Sleeping better; PHQ-9 4; no thoughts of self-harm |
6 systems reviewed. [S]
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Prednisone 20 mg oral tablet, two tablets (40 mg) by mouth each morning | 40 mg each morning | Oral route | 1964-03-09 to 1964-05-11 | completed | S |
| Prednisone 10 mg oral tablet, three tablets (30 mg) by mouth each morning for four weeks | 30 mg each morning for four weeks | Oral route | 1964-05-11 to 1964-06-08 | completed | S |
| Prednisone 20 mg oral tablet, one tablet (20 mg) by mouth each morning for four weeks | 20 mg each morning for four weeks | Oral route | 1964-06-08 to 1964-07-06 | completed | S |
| Prednisone 5 mg oral tablet, three tablets (15 mg) by mouth each morning for four weeks | 15 mg each morning for four weeks | Oral route | 1964-07-06 to 1964-08-03 | completed | S |
| Prednisone 10 mg oral tablet, one tablet (10 mg) by mouth each morning | 10 mg each morning | Oral route | 1964-08-03 to 1964-09-21 | completed | S |
| Methotrexate 2.5 mg oral tablet, six tablets (15 mg) by mouth once a week on Sundays | 15 mg once weekly | Oral route | 1964-03-09 to 1964-05-11 | completed | S |
| Methotrexate 2.5 mg oral tablet, eight tablets (20 mg) by mouth once a week on Sundays | 20 mg once weekly | Oral route | 1964-05-11 | active | S |
| Folic acid 1 mg oral tablet, one tablet by mouth daily | One tablet daily | Oral route | 1964-03-09 | active | S |
| Atovaquone 750 mg/5 mL oral suspension, 1500 mg (10 mL) by mouth once daily with food | 1500 mg once daily with food | Oral route | 1964-03-09 to 1964-07-06 | completed | S |
| Alendronate 70 mg oral tablet, one tablet by mouth once weekly on rising, with a full glass of water, staying upright for 30 minutes | One tablet once weekly | Oral route | 1964-03-16 | active | S |
| Metoprolol succinate 25 mg extended-release oral tablet, one tablet by mouth daily | One tablet daily | Oral route | 1964-03-09 | active | S |
| Cholecalciferol (vitamin D3) 25 mcg (1000 units) oral tablet, one tablet by mouth daily | One tablet daily | Oral route | 1964-05-11 | active | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 1964-08-24 | Body height | 170 | cm | S |
| 1964-08-24 | Body weight | 93 | kg | S |
| 1964-08-24 | Body mass index (BMI) [Ratio] | 32.2 | kg/m2 | S |
| 1964-08-24 | Systolic blood pressure | 130 | mm[Hg] | S |
| 1964-08-24 | Diastolic blood pressure | 82 | mm[Hg] | S |
| 1964-08-24 | Heart rate | 64 | /min | S |
| 1964-08-24 | Respiratory rate | 16 | /min | S |
| 1964-08-24 | Body temperature | 36.7 | Cel | S |
| 1964-08-24 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 1964-08-24 | Hemoglobin [Mass/volume] in Blood | 13 | g/dL | 12-15.5 g/dL | Normal | S |
| 1964-08-24 | Leukocytes [#/volume] in Blood by Automated count | 8.1 | 10*3/uL | 4-11 10*3/uL | Normal | S |
| 1964-08-24 | Lymphocytes [#/volume] in Blood by Automated count | 1.4 | 10*3/uL | 1-4.8 10*3/uL | Normal | S |
| 1964-08-24 | Platelets [#/volume] in Blood by Automated count | 248 | 10*3/uL | 150-400 10*3/uL | Normal | S |
| 1964-08-24 | Creatinine [Mass/volume] in Serum or Plasma | 0.9 | mg/dL | 0.59-1.04 mg/dL | Normal | S |
| 1964-08-24 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1959)/1.73 sq M | 77 | mL/min/{1.73_m2} | >=60 mL/min/1.73 m² | Normal | S |
| 1964-08-24 | Glucose [Mass/volume] in Serum or Plasma | 108 | mg/dL | 70-99 mg/dL | High | S |
| 1964-08-24 | Calcium [Mass/volume] in Serum or Plasma | 9.5 | mg/dL | 8.6-10.3 mg/dL | Normal | S |
| 1964-08-24 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 29 | U/L | 7-35 U/L | Normal | S |
| 1964-08-24 | Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 27 | U/L | 8-35 U/L | Normal | S |
| 1964-08-24 | Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma | 90 | U/L | 35-104 U/L | Normal | S |
| 1964-08-24 | Albumin [Mass/volume] in Serum or Plasma | 4.1 | g/dL | 3.5-5 g/dL | Normal | S |
| 1964-08-24 | Hemoglobin A1c/Hemoglobin.total in Blood | 6.2 | % | Below 5.7% is normal; 5.7 to 6.4% prediabetes; 6.5% or more diabetes | High | S |
| 1964-08-24 | 25-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Mass/volume] in Serum or Plasma | 34 | ng/mL | 30-100 ng/mL | Normal | S |
| 1964-08-24 | Natriuretic peptide.B prohormone N-Terminal [Mass/volume] in Serum or Plasma | 96 | pg/mL | <=125 pg/mL | Normal | S |
| 1964-08-24 | FVC measured/predicted | 90 | % | >=80% | Normal | S |
| 1964-08-24 | FEV1 measured/predicted | 89 | % | >=80% | Normal | S |
| 1964-08-24 | FEV1/FVC | 79 | % | >=70% | Normal | S |
| 1964-08-24 | Diffusion capacity.carbon monoxide/Predicted | 76 | % | >=80% | Low | S |
| 1964-08-24 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 4 | {score} | S |
Vital signs recorded on 1964-08-24; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| General | Well; weight 93.0 kg; blood pressure 130/82, pulse 64 and regular |
| Respiratory | Clear to auscultation |
| Cardiovascular | Regular rhythm; no murmur; device pocket normal |
| Mouth | No thrush or ulcers; voice clear |
| Skin | No rash, plaques or bruising |
| Psychiatric | Lively; planning her season |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Breathlessness on exertion and a dry cough for three months, worse on tour, with tiredness and chest tightness; she can no longer hold long phrases; bilateral hilar lymph node enlargement on today's chest radiograph; granulomas were reported at an abdominal operation twelve years ago, with no pathology report available: sarcoidosis must be confirmed by tissue and other causes excluded | resolved | confirmed | R06.09 | S — Synthetic presenting problem anchored to the documented breathlessness during performances and the 1952 granulomas. Superseded by the tissue diagnosis at the consultation. |
| Palpitations with two spells of light-headedness while singing; ECG today: sinus rhythm with first-degree atrioventricular block (PR 240 ms) and frequent ventricular ectopic beats: cardiac involvement must be looked for | resolved | confirmed | R00.2 | S — Synthetic finding; superseded when cardiac sarcoidosis was diagnosed. |
| Hypercalcemia: calcium 10.8 mg/dL with a high 1,25-dihydroxyvitamin D and a low 25-hydroxyvitamin D, while taking an over-the-counter calcium and vitamin D supplement; creatinine slightly raised | resolved | confirmed | E83.52 | S — Synthetic finding; resolved on treatment. |
| Pulmonary sarcoidosis with hilar and mediastinal lymph node involvement (Scadding stage II), confirmed by non-necrotizing granulomas on EBUS-guided lymph node aspiration with negative stains and cultures; mild restriction and reduced diffusing capacity; synthetic modern detail linked to her documented sarcoidosis | active | confirmed | D86.2 | S — Synthetic histology, stage and lung function; her biographer reports a diagnosis of sarcoidosis after granulomas were found at an operation (D, probable). |
| Acute viral laryngitis: three days of hoarseness, a sore throat and a mild dry cough after a cold, without fever, on prednisone 20 mg and methotrexate; rapid influenza and COVID-19 tests negative; no thrush; resolved | resolved | confirmed | J04.0 | S — Synthetic acute infection; not a historical claim. |
| Cardiac sarcoidosis: first-degree atrioventricular block, ventricular ectopy (6 percent of beats) with nonsustained ventricular tachycardia, left ventricular ejection fraction 47 percent, patchy late gadolinium enhancement of the basal septum and inferolateral wall, and matching focal FDG uptake on PET; synthetic modern detail linked to the documented private account that sarcoidosis was in her heart | active | confirmed | D86.85 | S — Synthetic cardiac findings; the account that her doctors told her sarcoidosis was in her heart rests on her biographer (D, probable), and the interpretation of her later heart disease is R. |
| Long-term systemic glucocorticoid treatment for sarcoidosis, with bone, glucose, blood pressure, infection and eye risks to manage | active | confirmed | Z79.52 | S — Synthetic treatment status. |
| Dual-chamber implantable cardioverter-defibrillator, placed after sustained monomorphic ventricular tachycardia was induced at electrophysiology study; remote monitoring | active | confirmed | Z95.810 | S — Synthetic device status after the synthetic implant. |
Protocol monitoring: items the monitoring protocol calls for at this visit. [S]
| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Imaging | Cardiac FDG-PET | Three to six months into treatment, and after major dose changes | Up to date | A week ago: no myocardial uptake; nodes smaller with low uptake |
| Imaging | Echocardiogram | With the repeat PET, and for symptoms | Up to date | A week ago: ejection fraction 54 percent |
| Imaging | Spirometry and diffusing capacity (FVC, FEV1, FEV1/FVC, DLCO) | At diagnosis, three months after starting treatment, then every three to six months while treatment changes | Completed today | FVC 90 percent, FEV1 89 percent, FEV1/FVC 79 percent, DLCO 76 percent of predicted |
| Laboratory | Methotrexate safety: blood count, liver tests and creatinine | Before starting; every two to four weeks for the first three months; then every eight to twelve weeks | Completed today | Hemoglobin 13.0 g/dL, white cells 8.1, lymphocytes 1.4, platelets 248; ALT 29, AST 27, alkaline phosphatase 90 U/L, albumin 4.1 g/dL; creatinine 0.90 mg/dL, eGFR 77; the monthly tests since May were normal; now every eight to twelve weeks |
| Laboratory | Serum calcium | At diagnosis, then at each treatment visit while it was raised or vitamin D is given | Completed today | 9.5 mg/dL on cholecalciferol |
| Laboratory | 25-hydroxyvitamin D | After replacement starts | Completed today | 34 ng/mL |
| Laboratory | Glucose and A1c on glucocorticoids | At each visit; A1c every three months | Completed today | Glucose 108 mg/dL; A1c 6.2% |
| Laboratory | NT-proBNP | At each cardiac review | Completed today | 96 pg/mL, normal |
| Examination | Defibrillator check (remote and in clinic) | Remote transmissions monthly and with any symptom; clinic check every three to six months | Completed today | Remote transmissions monthly: no ventricular tachycardia since March; clinic check booked this month |
| Examination | Eye examination | Yearly with sarcoidosis and on glucocorticoids | Up to date | Normal in March; next due in March |
| Imaging | Bone density (DXA) | Every one to three years on glucocorticoids | Up to date | March; repeat in two years |
| Medication safety | Pneumocystis prophylaxis | While prednisone is 20 mg or more with a second immunosuppressant | Not indicated | Stopped in July when prednisone fell below 20 mg |
| Medication safety | Vaccination on immunosuppression | Per schedule | Completed today | Recombinant zoster dose 2 given today; influenza and COVID-19 due in the autumn |
| Survey | Depression screen (PHQ-9) | At diagnosis and at each phase of treatment | Completed today | PHQ-9 4 |
| Self-management | Performing and travel plan | At each visit | Completed today | Autumn tour in the United States approved with rest days and the same medicine and device plan; a tour abroad next spring to be decided after the next review |
Goal progress:
Immunizations given today: Recombinant zoster vaccine, dose 2 of 2 [S]
Guideline basis: Crouser ED, et al. Diagnosis and Detection of Sarcoidosis. An Official American Thoracic Society Clinical Practice Guideline. Am J Respir Crit Care Med 2020;201(8):e26-e51 (PMID 32293205) (2020); Baughman RP, et al. ERS clinical practice guidelines on treatment of sarcoidosis. Eur Respir J 2021;58(6):2004079 (PMID 34140301) (2021); Birnie DH, et al. HRS expert consensus statement on the diagnosis and management of arrhythmias associated with cardiac sarcoidosis. Heart Rhythm 2014;11(7):1305-1323 (PMID 24819193) (2014); Cheng RK, et al. Diagnosis and Management of Cardiac Sarcoidosis: A Scientific Statement From the American Heart Association. Circulation 2024;149(21):e1197-e1216 (PMID 38634276) (2024); Humphrey MB, et al. 2022 American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis. Arthritis Rheumatol 2023;75(12):2088-2102 (PMID 37845798) (2022); Singh JA, et al. 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res 2012;64(5):625-639 (PMID 22473917) (methotrexate laboratory monitoring) (2012); Adult Immunization Schedule by Medical Condition and Other Indication (2026); Depression and Suicide Risk in Adults: Screening (2023)
Follow-up: Clinic device check this month. Methotrexate blood tests every eight to twelve weeks. Preventive visit in about six weeks with influenza and COVID-19 vaccines. Pulmonology review in three months. Next scheduled visit 1964-10-05: periodic adult preventive visit. [S]